Communiqués Lupin Limited NSE India S.E.

Actions

LUPIN

INE326A01037

Produits pharmaceutiques

Marché Fermé - NSE India S.E. 13:05:08 09/10/2026			Varia. 5j.	Varia. 1 janv.
1 956,50 ^INR	+1,01%		-3,68%	-7,25%

09/10	Lupin obtient l’autorisation de la FDA américaine pour une injection de vitamine K	MT
06/10	Lupin lance en Inde un inhalateur à triple association contre la bronchopneumopathie chronique	MT

Communiqués

20/08	Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland	AQ
18/08	Lupin Announces Approval from U.S. FDA for Pitolisant Tablets	AQ
06/07	Lupin Named Among World's Most Sustainable Companies by TIME and Statista	AQ
11/06	“Practically Complete”: Otsuka v. Lupin and the Chemistry of Missed Opportunity in Hatch-Waxman Litigation	AQ
04/06	Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection	AQ
02/04	Lupin Completes Acquisition of VISUfarma	AQ
02/02	Lupin : February 2, 2026 Lupin Launches Dasatinib Tablets in the United States	PU
02/02	Lupin : February 2, 2026 Lupin and TB Alliance Join Forces to Advance Telacebec for the Treatment of Tuberculosis and Other Mycobacterial Diseases	PU
23/01	Lupin : January 23, 2026 Lupin Receives Highest ESG Rating from CDP for Climate Change and Water Security	PU
21/01	Lupin : January 21, 2026 Lupin and Galenicum Sign License and Supply Agreement for Semaglutide in 23 Countries	PU
29/12	Lupin : December 29, 2025 Lupin Signs Exclusive Licensing Agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist	PU
18/12	Lupin : December 18, 2025 Lupin Signs Exclusive Licensing Agreement with Neopharmed for Gastroenterology Brand Plasil® in the Philippines and Brazil	PU
17/12	Lupin : December 17, 2025 Lupin Receives Positive CHMP Opinion for Biosimilar Ranibizumab	PU
17/12	Lupin : December 16, 2025 Lupin Receives EIR from US FDA for its Nagpur Injectable Facility	PU
17/12	Lupin : December 17, 2025 Lupin Receives EIR from US FDA for its Nagpur Injectable Facility	PU
16/12	Lupin : December 16, 2025 Lupin Secures SBTi Validation for Emission Reduction Targets	PU
12/12	Lupin : December 12, 2025 Lupin Manufacturing Solutions and PolyPeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain	PU
05/12	Lupin : December 5, 2025 Lupin Receives Tentative Approval from U.S. FDA for Siponimod Tablets	PU
04/12	Lupin : December 4, 2025 Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ (Pegfilgrastim-unne) in the United States	PU
01/12	Lupin : December 1, 2025 Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg™ (Pegfilgrastim-unne)	PU
15/11	Lupin : November 15, 2025 Lupin Announces Closure of Inspection by U.S. FDA at its Nagpur Unit-1 Facility with No Observations	PU
14/11	Lupin : November 14, 2025 Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™	PU
13/11	Lupin : November 13, 2025 Lupin Establishes a New Global Standard in Sustainable Pharma with an S&P Global ESG Score of 91	PU
12/11	Lupin : November 12, 2025 Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility	PU
12/11	Lupin : November 12, 2025 Lupin Manufacturing Solutions Unveils Dedicated Oncology Block at Vizag, India	PU